Evidence map›Paper›PMID 39263924›Full record

ArticleNutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition2025

Retrospective review of growth in pediatric intestinal failure after weaning from parenteral nutrition.

Anita M Nucci, Hillary Bashaw, Alexander Kirpich, Jeffrey Rudolph

Abstract readMulticenter Study
In one paragraph

Article in Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. A case report on the long-term use of teduglutide in a pediatric patient with short bowel syndrome.Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2026
    Article
  3. Retrospective review of growth in pediatric intestinal failure after weaning from parenteral nutrition.Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Anita M NucciDepartment of Nutrition, Georgia State University, Atlanta, Georgia, USA.ORCID http://orcid.org/0000-0001-8823-7384
Hillary BashawDivision of Gastroenterology, Hepatology, and Nutrition, Emory University School of Medicine, Atlanta, Georgia, USA.
Alexander KirpichDepartment of Population Health Sciences, School of Public Health, Georgia State University, Atlanta, Georgia, USA.
Jeffrey RudolphDivision of Pediatric Gastroenterology, Hepatology, and Nutrition, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID http://orcid.org/0000-0002-1763-7927

Funding

The study was funded by Takeda Pharmaceuticals USA, Inc, a wholly owned subsidiary of Takeda Pharmaceuticals Company Limited, Lexington, MA.
6 · The paper itself

Abstract

backgroundGrowth outcomes in children with intestinal failure (IF) after weaning from parenteral nutrition (PN) may be modified by primary diagnosis and interventions aimed at achieving enteral tolerance. We evaluated growth after weaning by diagnosis and intestinal transplant status and during treatment with the glucagon-like peptide-2 analog teduglutide.

methodsA two-center retrospective review was conducted on children diagnosed with IF at age <12 months. The z scores for weight and length/height were examined up to 5 years after PN weaning and in children who received teduglutide for >6 months. Data were reported as median and interquartile range (IQR).

resultsA total of 362 children (58% male and 72% White) were reviewed; 41% (n = 150) weaned from PN at age 1.5 years (IQR = 0.96-3). Weight and length/height data were available for 144 children; 46 received an intestinal transplant. Median weight and length/height z scores at weaning were -1.15 (IQR = -2.09 to -0.39) and -1.89 (IQR = -2.9 to -1.02), respectively. In those not transplanted, z scores remained stable (± 0.5 change). Children with small bowel atresia experienced accelerated linear growth (> +0.5 change) beginning in year 3. Most children transplanted experienced growth acceleration beginning in year 2. Fourteen children received teduglutide (median = 840 [IQR = 425-1530] days), and growth remained stable throughout treatment. Five were weaned from PN within 1 year.

conclusionWe observed stable growth with limited catch-up after PN weaning, with minimal variation by diagnosis, and during teduglutide therapy. Children who received an intestinal transplant experienced acceleration in weight and linear growth after weaning.

Indexed as

Intestinal FailureParenteral NutritionPeptidesBody HeightBody WeightChild, PreschoolFemaleGastrointestinal AgentsHumansInfantInfant, NewbornIntestinesMaleRetrospective StudiesGastrointestinal AgentsPeptidesteduglutideorgan transplantationparenteral nutritionpediatricsshort bowel syndrometeduglutide

Identifiers

PMID39263924
PMCPMC11713205

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.